Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Lumakras
Sotorasib is a targeted therapy used in the treatment of non-small cell lung cancer (NSCLC). It is a first-in-class KRAS G12C inhibitor, specifically designed to target the KRAS protein with a G12C mutation, which is present in approximately 13% of NSCLC patients. Sotorasib works by irreversibly binding to the inactive GDP-bound form of KRAS G12C, preventing it from switching to the active GTP-bound state, thereby inhibiting downstream signaling pathways that drive tumor growth and proliferation. This targeted approach offers a new treatment option for patients with this specific mutation.
Sotorasib is used to treat adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
Outcome:
Decreased sotorasib efficacy
Mechanism:
Increased sotorasib metabolism
Outcome:
Potential decrease in sotorasib efficacy
Mechanism:
Increased sotorasib metabolism
Outcome:
Minimal effect on sotorasib efficacy
Mechanism:
Slight increase in sotorasib metabolism
Most likely new formulation: Combination therapies with other targeted agents or immunotherapies (2024-2026, 80% confidence)
Based on clinical trial data and current usage trends, sotorasib has a high likelihood of remaining a key treatment option for KRAS G12C-mutated NSCLC in the foreseeable future.
Antineoplastic Agent, Kinase Inhibitor
Pyrazolopyrimidine